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Microbiology and drug resistance mechanisms of fully
resistant pathogens
Fiona M Walsh and Sebastian GB AmyesThe acquisition of vancomycin resistance by Gram-positive
bacteria and carbapenem resistance by Gram-negative
bacteria has rendered some hospital-acquired pathogens
impossible to treat. The resistance mechanisms employed are
sophisticated and very difficult to overcome. Unless alternative
treatment regimes are initiated soon, our inability to treat totally
resistant bacteria will halt other developments in medicine.
In the community, Gram-positive bacteria responsible for
pneumonia could become totally resistant leading to
increased mortality from this common infection, which would
have a more immediate impact on our current lifestyles.Addresses
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Antibiotic resistance is reaching a crisis because we are
running out of options to treat certain pathogenic bacteria,
mainly causing hospital-acquired infection but with the
potential to occur in the community. These multi-resis-
tant bacteria are generally identified by the acquisition of
specific resistance genes that are catastrophic. The devel-
opment of these resistant strains has built up progres-
sively over the past 20 years but has come to a head within
the past five. Although there were incidences of out-
breaks of multi-resistant bacteria in the past 10 years,
these are now becoming more frequent and more persis-
tent. The incidence of resistant bacteria used to fall back
a little after intervention but now this occurs less readily,
largely because we do not have effective antibiotics to
treat them. The extrapolation of fewer periods of remis-ncedirect.comsion from multi-drug resistance is, of course, that these
bacteria progress to pan-resistance where no class of
antibiotics can be used effectively to treat them. This
is the situation we are beginning to experience in some
clinical bacteria.
In this review, we focus on those bacteria where pan-
resistance has been or is set to be a problem.
Hospital-acquired infections
Some hospital-acquired pathogens are becoming totally
resistant to antibiotics, known examples include vanco-
mycin-resistant Enterococcus faecium and faecalis (VRE),
methicillin-resistant Staphylococcus aureus (MRSA), carba-
penem-resistant Acinetobacter baumannii and Pseudomonas
aeruginosa [1]. The failure is often attributed to the misuse
of antibiotics but the truth is probably that medicine has
moved on and too much is now expected from antibiotics
especially in the treatment of the immunocompromised.
These patients are a fertile breeding environment for
resistant bacteria, illustrated by the rise in Acinetobacter
and VRE infections in intensive care units, which is
largely attributed to infections in immunocompromised
patients; such pathogens are not considered particularly
pathogenic elsewhere.
Prior to the introduction of linezolid and synercid, VRE
were the first hospital bacteria to become resistant to all
available antibiotics. These organisms, often identified
as commensals of the human gastrointestinal tract, were
found to be the second most prevalent pathogen in
intensive care units in the United States. The vancomy-
cin resistance was initially identified to be conferred by an
operon of eight genes (Figure 1). Vancomycin resistance
is known to be transferable [2] and many transferable
resistance mechanisms are the result of single genes;
vancomycin resistance thus showed a quantum leap in
the sophistication of resistance determinants. The origi-
nal operon was bound by insertion sequences encoding
transposon Tn1546 [3]. The two genes of a classic class II
transposon ensure the migration of the gene between
replicons and different strains. Three essential genes
(vanH, vanA and vanX) are responsible for initiating an
alternative route to peptidoglycan synthesis that removes
the glycopeptide binding site of the D-alanyl-D-alanine
group on the pentapeptide. This alternative route in-
volves reversing the formation of the D-alanyl-D-alanine
moiety (VanX) to release free D-alanine, hydrogenating
pyruvate to form lactate (VanH), which is then ligated
with the freed D-alanine to provide D-alanyl-lactateCurrent Opinion in Microbiology 2004, 7:439–444
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The vanA operon [3].(VanA). This moiety is now incorporated in the normal
peptidoglycan synthesis and is no longer susceptible to
glycopeptide inhibition. On cross-linking during trans-
peptidation, the terminal lactate is removed, often by
the non-essential gene product VanY [4] (Figure 2). An
additional non-essential gene (vanZ) has no known func-
tion. The vanA operon is inducible, which is also rare for a
transferable resistance mechanism, by a two-component
induction system. VanS is a transmembrane protein that
autophosphorylates when it detects an incoming glyco-
peptide, which then phosphylates VanR that acts on the
essential promoter of the operon. The vanA operon is
effective against all glycopeptides that can initiate induc-
tion including teicoplanin. There are several similarFigure 2
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The mechanism of vancomycin resistance conferred by the vanA operon [3]
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Current Opinion in Microbiology 2004, 7:439–444operons in VRE; the second in importance is the vanB
operon in Tn1547, which confers lower resistance to
vancomycin and none to teicoplanin because this glyco-
peptide does not act as an inducer [5]. The vanC and vanE
operons employ serine instead of lactate as the glycopep-
tide-insusceptible terminal moiety in the pentapeptide in
peptidoglycan synthesis [4,6].
Variations in the vanA operon that are dependent on the
area that the host pathogen has been isolated have been
identified; for instance, the nucleotide sequence of oper-
ons from strains isolated in the United States differs from
those in the UK [7]. However, this operon can also vary
within a small geographical area and different insertionsUDP-MurNAC(pep)3-D-ala-D-lac
anA
Reduced vancomycin target
urNAC(pep)3-D-ala
VanY
vate
lac
UDP-MurNAC(pep)3
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. This diagram shows the mechanism of action of the vanA operon.
ere two D-alanine residues are ligated as a precursor. The vanA
ide D-alanine. The dehydrogenase VanH converts pyruvate to
tate. This becomes the new precursor and is incorporated into
bind vancomycin and thus provides resistance to it. The D-lactate
e same. The vanA operon also encodes a D,D-carboxypeptidase,
www.sciencedirect.com
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isolated from different health regions of Scotland; these
insertions have been linked to the capability to generate
teicoplanin resistance and may mirror teicoplanin policies
within individual health regions [8].
The proportion of S. aureus infections that are methicillin-
resistant in hospitals in the UK has risen alarmingly by
nearly 20-fold in the second half of the 1990s to just under
40% [9]. The spread of MRSA is known to be clonal in the
UK; there are two main types, EMRSA-15 and EMRSA-
16, first identified by phage typing [10]. These account
for more than 95% of all MRSA isolated. The integrity of
the types has been verified by genotyping. Six strains of
S. aureus have been sequenced and there is conservation
in 78% of the genome with considerable diversity in the
remaining 22%; however the main epidemic MRSA
strains do show some common characteristics in that they
all carry the seg and sei enterotoxin genes but, unlike less
common MRSA, do not carry the lukE leucocidin and splB
serine protease genes [10]. The use of methicillin resis-
tance as a marker is misleading; S. aureus acquired resis-
tance to this penicillin in the 1960s. It was the acquisition
of aminoglycoside resistance with methicillin resistance
that generated treatment problems; however the bacteria
could still be treated with glycopeptides. In the mid
1990s, Hiramatsu identified strains of MRSA isolated
in Japan that had intermediate susceptibility to vanco-
mycin, with minimum inhibitory concentrations (MICs)
of 8mg/L [11]. Hiramatsu also demonstrated that strains
from the same area that were vancomycin susceptible
could become intermediate at relative high frequency
[12]. Further investigation revealed that the bacteria had
increased their cell wall production and now had a much
thicker cell wall than the parent strains, which provided
some barrier to vancomycin [13]. Infections caused by
these strains, now known as VISA (vancomycin-inter-
mediate Staphylococcus aureus) could still be treated. An
in vitro experiment 10 years ago demonstrated that the
much more efficient vancomycin resistance mechanism of
the vanA operon from VRE could transfer and survive in
MRSA [14]; fortunately this was not found in clinical
strains. The situation changed in 2002 when the first
MRSA strain harbouring a vanA operon was found in a
patient in Michigan [15]. This was followed by reports
of a strain in Pennsylvania [16,17] and later in New York.
Courvalin recently described at the 14th European Con-
gress of Clinical Microbiology and Infectious Diseases
(ECCMID) in Prague that the vanA operon is very similar
to that in VRE but that the mobile element on which it is
located is not stable in S. aureus. To survive, Tn1546 had
to have sufficient opportunity to ‘jump’ into a more stable
replicon in S. aureus. The rarity of reports of vancomycin-
resistant S. aureus strains around the world, despite the
pressure that there must be to select them, suggests that
this operon has yet to find a sufficiently stable genetic
environment in MRSA, but surely it will.www.sciencedirect.comDespite the attention focussed on VRE and MRSA,
Gram-negative bacteria were the first pathogens respon-
sible for hospital-acquired infections. The most proble-
matic of these when ability to treat and pathogenicity are
considered are Acinetobacter baumannii and Pseudomonas
aeruginosa. Both these non-fermentors have few porins,
small in the case of A. baumannii, which have given them a
predisposition to survive in an antibiotic-rich environ-
ment. They are responsible for most hospital-acquired
pneumonia in patients previously treated with antibiotics
[18] as well as causing many other life-threatening infec-
tions. Their ability to rapidly acquire resistance to cepha-
losporins and fluoroquinolones has left the carbapenems
as the only remaining viable treatment option. Both
species can become resistant to carbapenems by genetic
mutation, to hyperproduction of the class C chromosomal
b-lactamase in P. aeruginosa increasing the number of
active sites able to bind carbapenems even if they are
inefficient at hydrolysing them or by loss of porins in
A. baumannii. However, it is their capability to accept
transferable b-lactamase genes that confer carbapenem
resistance at a level that will result in clinical failure that
causes most concern. In the mid 1990s, P. aeruginosa
strains isolated in Japan were found to harbour a transfer-
able class B metallo-b-lactamase called IMP-1 [19]. This
enzyme could increase the MIC to greater than 128mg/L
depending on the permeability characteristics of the
strain. This gene was thought originally to be confined
to southeast Asia but it and a myriad of similar genes
(blaIMP-2 – blaIMP-12) have now been isolated in P. aeru-
ginosa and other Gram-negative bacteria from around the
world. A similar class of b-lactamases (VIM 1–4) have
been found in Asia and Europe, almost exclusively in
P. aeruginosa [20]. The extent and diversity of these
enzymes suggests that they will be very difficult to
overcome.
Although the blaIMP genes can migrate into A. baumannii,
they do not appear to be a major contributor to carbape-
nem resistance. A new group of transferable class D b-
lactamases have emerged almost exclusively in A. bau-
mannii and are capable of increasing the MIC of imipe-
nem to 16mg/L or higher. The first of these enzymes
(OXA-23) was found in Scotland 15 years ago [21]. This
enzyme was transferable [22] and had a unique amino
acid sequence [23]. Thought to be an isolated observa-
tion, blaOXA-23 has subsequently been found in Brazil [24]
and very recently has been reported to be responsible for
two outbreaks in southeast England. A second group of
class D carbapenemases has been found in A. baumannii
isolated largely in southwest Europe, these enzymes
share about 60% homology with OXA-23 [25]. The suc-
cess of the vancomycin-resistance operon in Gram-
positive pathogens and transferable carbapenamses in
Gram-negative pathogens is certain to make treatment
of hospital infection very difficult or near impossible. The
introduction of linezolid and the streptogrammins mightCurrent Opinion in Microbiology 2004, 7:439–444
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teria although problems have already been identified, but
the continuing infiltration in Gram-negative bacteria by
carbapenamases is likely to render these bacteria impos-
sible to control as has already been experienced in some
parts of the world [26].
Among community-acquired infections in the developed
world, those caused by Streptococcus pneumoniae are
the most likely to develop resistance progressively to
the major groups of available antibiotics. In general, the
resistance most associated with S. pneumoniae is peni-
cillin resistance. However, penicillin resistance has pre-
viously included intermediate resistance and thus falsely
elevated the levels of penicillin resistance repor-
ted worldwide. Currently, penicillin resistance in S.
pneumoniae varies from 0% resistance in the Netherlands
to 71.5% in South Korea [27]. Although this is proble-
matic, penicillin resistance is at least concentrated in
only certain countries, whereas the levels of resistance
to macrolides are both high and widespread throughout
the world. In many countries macrolide resistance is
higher than penicillin resistance and does not appear
to be arresting. One such country is Hungary, where
penicillin resistance is 2% (37% intermediate) but
erythromycin resistance is 41.7% [28], another is Italy
with penicillin resistance at 10.1% but erythromycin
resistance at 42.9% [27].
The most frequently identified macrolide resistance
mechanisms are methylation of the target site associated
with the ermB gene or efflux encoded by the mef genes.
These two mechanisms have been identified worldwide,
where testing has been performed. However, distribution
of these genes has been suggested to be continent
dependent. Macrolide resistance in the USA and Canada
is predominantly mediated by the mef genes and so has
the M phenotype. While in Europe, macrolide resistance
is mostly associated with the presence of the ermB gene
and the MLSB phenotype. Recently, the resistance pro-
file of Europe has begun to change as resistance data has
been collected from countries other than those with a
high level of macrolide resistance. The most recent
publications currently indicate that within Europe resis-
tance to macrolides due to the mef gene is increasing,
whereas resistance due to the ermB gene is remaining
static. This is happening both in countries with high
macrolide resistance, such as Italy [29] and low macrolide
resistance such as Finland [30]. The efflux phenotype is
the predominant macrolide resistance mechanism in the
UK, Sweden, Finland, Germany, Switzerland and Austria
[31,32]. Are these isolates or their genes spreading to the
rest of Europe? The total European picture is unclear but
there are trends emerging that the mef gene mediated
resistance is beginning to take over the ermB-based
resistance. If this is the case then we need to know
how this is happening and why. This is of most impor-Current Opinion in Microbiology 2004, 7:439–444tance in relation to the new class of antibiotics, the
ketolides. Telithromycin has excellent activity against
ermB and mef mediated macrolide resistances [27]. Muta-
tion studies have identified that S. pneumoniae resistant to
telithromycin have occurred with fewer passages or gen-
erations in S. pneumoniae with the ermB gene than those
containing the mef genes [33,34]. While the increasing
presence of the mef macrolide resistance augurs well for
the ketolides, we do need more research into the effects
of this gene and the effect of efflux on the new ketolide
class.
The results of genotyping studies on S. pneumoniae
have identified a group of 16 multi-drug resistant clones
circulating the world [35]. Resistance to macrolides is
usually mediated by genes on mobile elements. The
relationship between macrolide resistant isolates is not
clonal but depends on the movement of resistance genes
between isolates [36]. Penicillin resistance is not media-
ted by mobile elements. Therefore, macrolide resistance
is spread by gene movement and penicillin resistance is
spread by isolate movement. Thus, as gene movement is
a more frequent event than isolate movement the ability
for macrolide resistance to spread is of higher concern
than penicillin resistance spread. We believe that the
increase in macrolide resistance as opposed to penicillin
resistance is associated with the ability of the macrolide
resistance genes to transfer more efficiently than the
penicillin resistant isolates to disseminate.
In recent years, research into macrolide resistance has
dramatically increased both in the number of isolates
studied and the number of countries involved in surveil-
lance of macrolide resistance in S. pneumoniae. Studies of
macrolide resistance and in particular surveillance studies
have not only focused on the levels of macrolide resis-
tance but have also investigated the mechanisms of
resistance used by the isolates in each country. The
increased level of research both within clinical isolates
and in vitro has provided us with a greater knowledge of
the mechanisms of macrolide resistance and particularly
the less frequently identified resistance mechanisms.
The mechanisms of macrolide-resistance in S. pneumoniae
were initially confined to the identification of either
the erm or mef genes. The study of macrolide resistance
was then expanded to include macrolide resistant S.
pneumoniae, which did not harbour either the ermB or
mefA genes. This included investigation of the 23S rRNA
alleles and the L4 and L22 riboproteins for mutations
[37]. Following the publication of this paper, isolates
proving negative for the ermB or mef genes were routinely
analysed for mutations in these regions. While resistance
is predominated by the ermB or mef genes these mutations
do also occur in clinical isolates. As research moved out-
side of the ermB and mef genes further discoveries were
made: there are two types of mef gene, mefA and mefE
carried by two different transposons, the presence of anwww.sciencedirect.com
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resistance and isolates containing both ermB and mef
genes were also identified [38–40].
What are the antibiotics of last resort for the treatment
of macrolide resistant, penicillin and multi-drug resistant
S. pneumoniae? Currently, they are linezolid and vanco-
mycin. Unlike S. aureus and enterococci vancomycin-resis-
tant S. pneumoniae have not yet been identified. However,
clinical strains of vancomycin tolerant S. pneumoniae have
been identified [41,42]. Tolerance is the ability of bac-
teria to survive in the presence of an antibiotic, neither
growing nor undergoing lysis. It is thought to be a pre-
cursor to resistance development. As vancomycin toler-
ance is not routinely documented in the surveillance
studies as with macrolide resistance it is difficult to
identify the full extent of vancomycin tolerance.
Conclusions
Antibiotic resistance in these pathogens is set to change
the way we view medicine; elective surgery with the risk
of an untreatable infection is an unattractive option and
transplantation with the likelihood that any infection may
lead inevitably to death is a gamble that many may not be
prepared to take. However, total resistance in the com-
munity is likely to have a more immediate impact on the
way we live, few parents would be prepared to send their
children to day-care centres if the danger of untreatable
infection is high.
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